Neurocrine Biosciences (NBIX) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 1.6% versus a loss of 6.8%. Over five years, NBIX leads with a +35.1% price change compared with -16.4% for QGEN. Neurocrine Biosciences is the larger company by market cap ($14.36 billion vs $9.20 billion), about 1.6 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 17.0x for Qiagen N.V.). Qiagen N.V. pays a dividend yielding 0.82%, while Neurocrine Biosciences does not currently pay one. Qiagen N.V. converts more of its revenue into profit, with a net margin of 20.3% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | QGEN |
|---|---|---|
| Share price | $141.25 | $44.53 |
| Market cap | $14.36B | $9.20B |
| 1-day change | -1.55% | -0.58% |
| YTD return | -0.41% | -0.98% |
| 1-year return | +1.56% | -6.76% |
| 5-year return | +35.12% | -16.44% |
| P/E ratio (TTM) | 20.71 | 22.60 |
| Forward P/E | 11.89 | 17.04 |
| EPS (TTM) | $6.82 | $1.97 |
| Dividend yield | 0.00% | 0.82% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | $2.86B | $2.09B |
| Revenue growth (YoY) | +21.45% | +5.65% |
| Net income (latest FY) | $478.60M | $424.88M |
| Gross margin | 98.18% | 62.18% |
| Operating margin | 21.64% | 22.29% |
| Net margin | 16.73% | 20.33% |
| 52-week high | $186.12 | $57.82 |
| 52-week low | $122.14 | $32.53 |
| Distance from 52-week high | -24.11% | -22.99% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +46.75% | +6.15% |
| Average volume | 1.30M | 2.58M |
| Shares outstanding | 101.65M | 206.50M |
| Employees | 2,500 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs +5.65%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
NBIX vs QGEN FAQ
Which is bigger, Neurocrine Biosciences or Qiagen N.V.?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.36B compared with $9.20B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, NBIX or QGEN?
NBIX returned +1.56% over the past 12 months, compared with -6.76% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or QGEN?
NBIX has the lower trailing P/E at 20.7, versus 22.6 for QGEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Neurocrine Biosciences or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.82%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Neurocrine Biosciences and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.